Pune-based Gennova Biopharmaceuticals Ltd on Tuesday said its mRNA COVID-19 booster vaccine against the Omicron variant, GEMCOVAC-OM, has received emergency use authorisation from the Drugs ...

Emcure Pharmaceuticals Ltd. and its biotech subsidiary, Gennova Biopharmaceuticals Ltd. have amicably resolved all legal disputes with HDT Bio Corp. The litigation between them, including before US ...

New Delhi, Jun 29 (PTI) Gennova Biopharmaceuticals Ltd on Wednesday said it is ready with 70 lakh dosages of its Gemcovac-19 vaccine, the first indigenously developed mRNA vaccine against COVID-19 ...

Gennova Biopharmaceuticals Ltd on Wednesday said it is ready with 70 lakh dosages of its Gemcovac-19 vaccine, the first indigenously developed mRNA vaccine against Covid-19 to be approved for ...

Gennova Biopharmaceuticals Ltd, a Pune-based company, announced on Tuesday that its mRNA Covid-19 booster vaccine - Gemcovac - against Omicron variant of SARS-CoV-2 has received emergency use ...

Emcure Pharmaceuticals Ltd and its arm Gennova Biopharmaceuticals have settled all legal disputes with HDT Bio Corp and have signed a long-term agreement to develop mRNA vaccines, the company said ...

Gennova Biopharmaceuticals has launched a paediatric packsize of pegaspargase, used to treat an orphan disease like Acute Lymphoblastic Leukaemia (ALL), a rare and challenging form of blood cancer ...

Follow us on LinkedIn. About Gennova Gennova Biopharmaceuticals Ltd., headquartered in Pune, India, is a biotechnology company dedicated to the research, development, production, and ...

Gennova Biopharmaceuticals Ltd., a subsidiary of Emcure Pharmaceuticals Ltd., said its mRNA vaccine – GEMCOVAC™-19 – against Covid‑19, has received Emergency Use Authorisation (EUA ...

The company will sell the vaccine under the brand name GEMCOVAC-19. "Gennova Biopharmaceuticals Ltd., a subsidiary of Emcure Pharmaceuticals Ltd., announced that its mRNA vaccine -- GEMCOVAC-19 ...

CEO of Gennova Biopharmaceuticals Ltd, said. GEMCOVAC-OM is a thermostable vaccine which does not require ultra-cold chain infrastructure, making it easy for pan-India deployment ...